Data on migration of the non-invasive breast cancer cell line, MCF-7 treated with Bevacizumab using Real Time Cell Analyzer (RTCA)

Layal EL-Hajjar; Abdullah Shaito; Nour Jalaleddine; Kazem Zibara; Jalal M. Kazan; Jamal El-Saghir; Marwan El-Sabban

Data in Brief (Feb 2019)

Data on migration of the non-invasive breast cancer cell line, MCF-7 treated with Bevacizumab using Real Time Cell Analyzer (RTCA)

Layal EL-Hajjar,
Abdullah Shaito,
Nour Jalaleddine,
Kazem Zibara,
Jalal M. Kazan,
Jamal El-Saghir,
Marwan El-Sabban

Affiliations

Layal EL-Hajjar: Department of Biological and Environmental Sciences, Faculty of Science, Beirut Arab University, Beirut, Lebanon
Abdullah Shaito: Department of Biological and Environmental Sciences, Faculty of Science, Beirut Arab University, Beirut, Lebanon
Nour Jalaleddine: Department of Biological and Chemical Sciences, Faculty of Arts and Sciences, Lebanese International University, Beirut, Lebanon
Kazem Zibara: ER045 – Laboratory of Stem Cells, PRASE, Biology Department, Faculty of Sciences, Lebanese University, Beirut, Lebanon
Jalal M. Kazan: Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
Jamal El-Saghir: Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
Marwan El-Sabban: Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon; Correspondence to: Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon.

Journal volume & issue: Vol. 22
pp. 635 – 638

Abstract

Read online

Bevacizumab or Avastin® (Av), the recombinant antibody targeting VEGF, improves progression-free but not overall survival of metastatic breast cancer patients due to development of Av resistance. We showed that Av-therapy-induced inflammatory microenvironment contributes to the refractoriness to Av treatment. Here we present data regarding the effect of Av treatment on migration of a non-invasive breast cancer cell line, MCF-7. The data presented hereis related to the research article “Bevacizumab induces inflammation in MDA-MB-231 breast cancer cell line and in a mouse model” (Hajjar et al., 2018). Keywords: Bevacizumab, MCF-7, Migration, RTCA

Published in Data in Brief

ISSN: 2352-3409 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Medicine (General): Computer applications to medicine. Medical informatics; Science: Science (General)
Website: http://www.journals.elsevier.com/data-in-brief/

About the journal